Neural deficits contribute to respiratory insufficiency in Pompe disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 23, 2009, Pages 9419-9424

  DeRuisseau, Lara R ^a   Fuller, David D ^b   Qiu, Kai ^b   DeRuisseau, Keith C ^c   Donnelly Jr , William H ^d   Mah, Cathryn ^d   Reier, Paul J ^d   Byrne, Barry J ^d  

^a Scott)   (United States)

^b Clinical and Health Psychology   (United States)

^c Department of Applied Physiology and Kinesiology   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Glycogenosis; Motor neuron; Muscular dystrophy; Myopathy

Indexed keywords

ALPHA GLUCOSIDASE; GLYCOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING; CENTRAL NERVOUS SYSTEM; CERVICAL SPINAL CORD; CONTROLLED STUDY; DIAPHRAGM; DISEASE SEVERITY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HYPERCAPNIA; INSPIRATORY CAPACITY; LUNG VENTILATION; LYSOSOME; MALE; MOTONEURON; MOUSE; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; NEUROPHYSIOLOGY; NONHUMAN; PHRENIC NERVE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY FAILURE; SKELETAL MUSCLE;

AGE OF ONSET; ALPHA-GLUCOSIDASES; ANIMALS; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; MALE; MICE; MICE, TRANSGENIC; PHRENIC NERVE; RESPIRATORY INSUFFICIENCY; RESPIRATORY MUSCLES; SPINAL CORD;

ANIMALIA; MUS;

EID: 67249094212     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0902534106     Document Type: Article

References (48)

1. Brown AM, Baltan Tekkök S, Ransom BR (2004) Energy transfer from astrocytes to axons: The role of CNS glycogen. Neurochem Int 45:529-536. (Pubitemid 38739480)
2. Vilchez D, et al. (2007) Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 10:1407-1413. (Pubitemid 350014686)
3. Sidman RL, et al. (2008) Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. J Neuropathol Exp Neurol 67:803-818.
4. Hirschhorn R, Reuser AJJ (2001) Glycogen storage disease type II; acid α-glucosidase (acid maltase) deficiency. In: The Metabolic and Molecular Basis of Inherited Disease, eds Scriver CR, Beaudet AL, Sly WS, Valle D (McGraw-Hill, New York), 8th Ed, Chapter 135.
5. Lejeune N, Thines-Sempoux D, HersHG(1963) Tissue fractionation studies. 16. Intracellular distribution and properties of alpha-glucosidases in rat liver. Biochem J 86:16-21.
6. Jeffrey PL, Brown DH, Brown BI (1970) Studies of lysosomal alpha-glucosidase. I. Purification and properties of the rat liver enzyme Biochemistry 9:1403-1415.
7. Schoser B, Hill V, Raben N (2008) Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics 5:569-578.
8. Raben N, Plotz P, Byrne BJ (2002) Correction of the enzymatic and functional deficits in a model of Pompe disease by using adeno-associated virus vectors. Curr Mol Med 2:145-166.
9. Teng YT, Su WJ, Hou JW, Huang SF (2004) Infantile-onset glycogen storage disease type II (Pompe disease): Report of a case with genetic diagnosis and pathological findings. Chang Gung Med J 27:379-384. (Pubitemid 38943579)
10. Mancall EL, Aponte GE, Berry RG (1965) Pompe's disease (diffuse glycogenosis) with neuronal storage. J Neuropathol Exp Neurol 24:85-96.
11. Martin JJ, de Barsy T, van Hoof F, Palladini G (1973) Pompe's disease: An inborn lysosomal disorder with storage of glycogen.Astudy of brain and striated muscle. Acta Neuropathol (Berl) 23:229-244.
12. Gambetti P, DiMauro S, Baker L (1971) Nervous system in Pompe's disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol 30:412-430.
13. Martini C, et al. (2001) Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurology 57:906-908. (Pubitemid 32845520)
14. Chien YH, Lee NC, Peng SF, Hwu WL(2006) Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. Pediatr Res 60:349-352. (Pubitemid 44267751)
15. Hogan GR, Gutmann L, Schmidt R, Gilbert E (1969) Pompe's disease. Neurology 19:894-900.
16. Winkel LP, et al. (2005) The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 252:875-884. (Pubitemid 41186956)
17. Kikuchi T, et al. (1998) Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 101:827-833. (Pubitemid 28096080)
18. Raben N, et al. (2001) Conditional tissue-specific expression of the acid alphaglucosidase (GAA) gene in the GAA knockout mice: Implications for therapy. Hum Mol Genet 10:2039-2047. (Pubitemid 32998816)
19. Raben N, et al. (1998) Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 273:19086-19092. (Pubitemid 28366303)
20. Seifert BL, et al. (1992) Development of obstruction to ventricular outflow and impairment of inflow in glycogen storage disease of the heart: Serial echocardiographic studies from birth to death at 6 months. Am Heart J 123:239-242.
21. Tankersley CG, Fitzgerald RS, Kleeberger SR (1994) Differential control of ventilation among inbred strains of mice. Am J Physiol 267:R1371-R1377. (Pubitemid 2164529)
22. Silva AJ, et al. (1997) Mutant mice and neuroscience: Recommendations concerning genetic background; Banbury conference on genetic background in mice. Neuron 19:755-759.
23. Enhorning G, van Schaik S, Lundgren C, Vargas I (1998) Whole-body plethysmography, does it measure tidal volume of small animals? Can J Physiol Pharmacol 76:945-951. (Pubitemid 29157543)
24. Mortola JP, Frappell PB (1998) On the barometric method for measurements of ventilation, and its use in small animals. Can J Physiol Pharmacol 76:937-944. (Pubitemid 29157542)
25. Baker TL, Mitchell GS (2000) Episodic but not continuous hypoxia elicits long-term facilitation of phrenic motor output in rats. J Physiol 529(Pt 1):215-219.
26. Fuller DD (2005) Episodic hypoxia induces long-term facilitation of neural drive to tongue protrudor and retractor muscles. J Appl Physiol 98:1761-1767. (Pubitemid 40570787)
27. Eldridge FL (1975) Relationship between respiratory nerve and muscle activity and muscle force output. J Appl Physiol 39:567-574.
28. Henneman E, Somjen G, Carpenter DO (1965) Functional significance of cell size in spinal motoneurons. J Neurophysiol 28:560-580.
29. Road JD (1990) Phrenic afferents and ventilatory control. Lung 168:137-149. (Pubitemid 20175221)
30. Romaniuk JR, Supinski GS, DiMarco AF (1993) Reflex control of diaphragm activation by thoracic afferents. J Appl Physiol 75:63-69. (Pubitemid 23221957)
31. Iscoe S, Grélot L, Bianchi AL (1990) Responses of inspiratory neurons of the dorsal respiratory group to stimulation of expiratory muscle and vagal afferents. Brain Res 507:281-288. (Pubitemid 20054110)
32. Teng YD, et al. (2003) Serotonin 1A receptor agonists reverse respiratory abnormalities in spinal cord-injured rats. J Neurosci 23:4182-4189. (Pubitemid 36958438)
33. Zellweger H, Dark A, Abu-HaidarGA(1955) Glycogen disease of skeletal muscle; report of two cases and review of literature. Pediatrics 5:715-732.
34. Willemsen MA, Jira PE, Gabreels FJ, van der Ploeg AT, Smeitink JA (1998) Three hypotonic neonates with hypertrophic cardiomyopathy: Pompe's disease. Ned Tijdschr Geneeskd 142:1388-1392. (Pubitemid 28302871)
35. Teng YT, Su WJ,Hou JW, Huang SF (2004) Infantile-onset glycogen storage disease type II (Pompe disease): Report of a case with genetic diagnosis and pathological findings. Chang Gung Med J 27:379-384. (Pubitemid 38943579)
36. Clement DH, Godman GC (1950) Glycogen disease resembling mongolism, cretinism, and amytonia congenita; case report and review of literature. J Pediatr 36:11-30.
37. Ponce E, Witte DP, Hirschhorn R, Huie ML, Grabowski GA (1999) Murine acid alphaglucosidase: Cell-specific mRNA differential expression during development and maturation. Am J Pathol 154:1089-1096. (Pubitemid 29169743)
38. Ohtsuka T, et al. (1999) Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. EMBO J 18:2196-2207.
39. Raben N, et al. (2003) Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80:159-169. (Pubitemid 37272242)
40. Vanden Hout JM, et al. (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448-e457.
41. Winkel LP, et al. (2004) Enzyme replacement therapy in late-onset Pompe's disease: A three-year follow-up. Ann Neurol 55:495-502. (Pubitemid 38391966)
42. van Capelle CI, et al. (2008) Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 18:447-452.
43. Beck M (2007) New therapeutic options for lysosomal storage disorders: Enzyme replacement, small molecules and gene therapy. Hum Genet 121:1-22. (Pubitemid 46421136)
44. Lane MA, Fuller DD, White TE, Reier PJ (2008) Respiratory neuroplasticity and cervical spinal cord injury: Translational perspectives. Trends Neurosci 31:538-547.
45. Mah C, et al. (2007) Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther 15:501-507. (Pubitemid 46306592)
46. Lo S, Russell JC, Taylor AW (1970) Determination of glycogen in small tissue samples. J Appl Physiol 28:234-236.
47. Guth L, Watson PK (1968) A correlated histochemical and quantitative study on cerebral glycogen after brain injury in the rat. Exp Neurol 22:590-602.
48. Teng YD, Mocchetti I, Taveira-DaSilva AM, Gillis RA, Wrathall JR (1999) Basic fibroblast growth factor increases long-term survival of spinal motor neurons and improves respiratory function after experimental spinal cord injury. J Neurosci 19:7037-7047. (Pubitemid 29380129)